Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery

Journal of Controlled Release

Volumn 102, Issue 1, 2005, Pages 85-99

  Chong, Carrie S W ^a   Cao, Min ^a   Wong, Winnie W ^a   Fischer, Karl P ^a   Addison, William R ^a   Kwon, Glen S ^a,b   Tyrrell, D Lorne ^a   Samuel, John ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Hepatitis B; Monophosphoryl lipid A; Nanoparticles; PLGA; Vaccines

Indexed keywords

ANTIGENS; DISEASES; IMMUNIZATION; NANOSTRUCTURED MATERIALS; PHOSPHOLIPIDS; VACCINES; VIRUSES;

HEPATITIS B CORE ANTIGEN (HBCAG); INTERFERON-Γ (IF-Γ); MONOPHOSPHOLIPID A (MPLA); POLY(D,L-LACTIC-ACID-CO-GLYCOLIC ACID) PLGA);

IMMUNOLOGY;

GAMMA INTERFERON; HEPATITIS B CORE ANTIGEN; HEPATITIS VACCINE; IMMUNOMODULATING AGENT; MONOPHOSPHOLIPID A; NANOPARTICLE; PHOSPHOLIPID DERIVATIVE; POLYGLACTIN; RECOMBINANT ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; ENCAPSULATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; IMMUNE RESPONSE; IMMUNIZATION; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; TH1 CELL; VIRUS IMMUNITY;

EID: 11844263890     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2004.09.014     Document Type: Article

References (69)

1. R.P. Perrillo Treatment of chronic hepatitis with interferon: experience in Western countries Semin. Liver Dis. 9 1989 240 248
2. J.F. Hu, Z. Cheng, F.V. Chisari, T.H. Vu, A.R. Hoffman, and T.C. Campbell Repression of hepatitis B virus (HBV) transgene and HBV-induced liver injury by low protein diet Oncogene 15 1997 2795 2801
3. R.P. Beasley, and L.Y. Hwang Postnatal infectivity of hepatitis B surface antigen-carrier mothers J. Infect. Dis. 1983 1983 185 190
4. C.E. Stevens, R.P. Beasley, J. Tsui, and W.C. Lee Vertical transmission of hepatitis B antigen in Taiwan N. Engl. J. Med. 292 1975 771 774
5. T. Ishikawa, D. Kono, J. Chung, P. Fowler, A. Theofilopoulos, S. Kakumu, and F.V. Chisari Polyclonality and multispecificity of the CTL response to a single viral epitope J. Immunol. 161 1998 5842 5850
6. M.K. Maini, C. Boni, G.S. Ogg, A.S. King, S. Reignat, C.K. Lee, J.R. Larrubia, G.J. Webster, A.J. McMichael, C. Ferrari, R. Williams, D. Vergani, and A. Bertoletti Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection Gastroenterology 117 1999 1386 1396
7. M.K. Maini, G. Casorati, P. Dellabona, A. Wack, and P.C. Beverley T cell clonality in immune responses Immunol. Today 20 1999 262 266 (comment)
8. B. Rehermann, D. Lau, J.H. Hoofnagle, and F.V. Chisari Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection J. Clin. Invest. 97 1996 1655 1665
9. C. Boni, A. Bertoletti, A. Penna, A. Cavalli, M. Pilli, S. Urbani, P. Scognamiglio, R. Boehme, R. Panebianco, F. Fiaccadori, and C. Ferrari Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B J. Clin. Invest. 102 1998 968 975
10. M.U. Mondelli, F.V. Chisari, and C. Ferrari The cellular immune response to nucleocapsid antigens in hepatitis B virus infection Springer Semin. Immunopathol. 12 1990 25 31
11. C. Ferrari, A. Penna, A. Bertoletti, A. Valli, A. Antoni, T. Giuberti, A. Cavalli, M. Petit, and F. Fiaccadori Cellular immune response to hepatitis B virus-encoded antigens in acute and chronic hepatitis B virus infection J. Immunol. 145 1990 3442 3449
12. D.R. Milich, A. McLachlan, G.B. Thornton, and J.L. Hughes Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site Nature 329 1987 547 549
13. H.F. Lohr, S. Krug, W. Herr, S. Weyer, J. Schlaak, T. Wolfel, G. Gerken, and K.H. Meyer zum Buschenfelde Quantitative and functional analysis of core-specific T-helper cell and CTL activities in acute and chronic hepatitis B Liver 18 1998 405 413
14. F. Siegel, M. Lu, and M. Roggendorf Coadministration of gamma interferon with DNA vaccine expressing Woodchuck Hepatitis Virus (WHV) core antigen enhances the specific immune response and protects against WHV infection J. Virol. 75 2001 5036 5042
15. G.K. Lau, D. Suri, R. Liang, E.I. Rigopoulou, M.G. Thomas, I. Mullerova, A. Nanji, S.T. Yuen, R. Williams, and N.V. Naoumov Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen Gastroenterology 122 2002 614 624
16. G.J. Webster, S. Reignat, D. Brown, G.S. Ogg, L. Jones, S.L. Seneviratne, R. Williams, G. Dusheiko, and A. Bertoletti Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy J. Virol. 78 2004 5707 5719
17. A. Penna, G. Del Prete, A. Cavalli, A. Bertoletti, M.M. D'Elios, R. Sorrentino, M. D'Amato, C. Boni, M. Pilli, F. Fiaccadori, and C. Ferrari Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B Hepatology 25 1997 1022 1027
18. P. Periti, T. Mazzei, and E. Mini Clinical pharmacokinetics of depot leuprorelin Clin. Pharmacokinet. 41 2002 485 504
19. H. Okada, and H. Toguchi Biodegradable microspheres in drug delivery Crit. Rev. Ther. Drug Carr. Syst. 12 1995 1 99
20. R. Audran, K. Peter, J. Dannull, Y. Men, E. Scandella, M. Groettrup, B. Gander, and G. Corradin Encapsulation of peptides in biodegradable microspheres prolongs their MHC class-I presentation by dendritic cells and macrophages in vitro Vaccine 21 2003 1250 1255
21. H. Sun, K.G.J. Pollock, and J.M. Brewer Analysis of the role of vaccine adjuvants in modulating dendritic cell activation and antigen presentation in vitro Vaccine 21 2003 849 855
22. K.B. Walker, D.K. Xing, D. Sesardic, and M.J. Corbel Modulation of the immune response to tetanus toxoid by polylactide-polyglycolide microspheres Dev. Biol. Stand. 92 1998 259 267
23. R.S. Raghuvanshi, Y.K. Katare, K. Lalwani, M.M. Ali, O. Singh, and A.K. Panda Improved immune response from biodegradable polymer particles entrapping tetanus toxoid by use of different immunization protocol and adjuvants Int. J. Pharm. 245 2002 109 121
24. L. Shi, M.J. Caulfield, R.T. Chern, R.A. Wilson, G. Sanyal, and D.B. Volkin Pharmaceutical and immunological evaluation of a single-shot hepatitis B vaccine formulated with PLGA microspheres J. Pharm. Sci. 91 2002 1019 1035
25. T. Jung, R. Koneberg, K.D. Hungerer, and T. Kissel Tetanus toxoid microspheres consisting of biodegradable poly(lactide-co-glycolide)- and ABA-triblock-copolymers: immune response in mice Int. J. Pharm. 234 2002 75 90
26. J.R. Baldridge, and R.T. Crane Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines Methods 19 1999 103 107
27. A. Moore, L. McCarthy, and K.H.G. Mills The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1 Vaccine 17 1999 2517 2527
28. J.T. Ulrich, and K.R. Myers Monophosphoryl lipid A as an adjuvant. Past experiences and new directions Pharm. Biotechnol. 6 1995 495 524
29. T. Uchida, K. Shiosaki, Y. Nakada, K. Fukada, Y. Eda, S. Tokiyoshi, N. Nagareya, and K. Matsuyama Microencapsulation of hepatitis B core antigen for vaccine preparation Pharm. Res. 15 1998 1708 1713
30. Z.-H. Jiang, M.V. Bach, W.A. Budzynski, M.J. Krantz, R.R. Koganty, and B.M. Longenecker Lipid A structures containing novel lipid moieties: synthesis and adjuvant properties Bioorg. Med. Chem. Lett. 12 2002 2193 2196
31. Z.-H. Jiang, and R.R. Koganty Synthetic vaccines: the role of adjuvants in immune targeting Curr. Med. Chem. vol. 10 2003 Bentham Science Publishers 1423 1439
32. Z.H. Jiang, W.A. Budzynski, L.N. Skeels, M.J. Krantz, and R.R. Koganty Novel lipid A mimetics derived from pentaerythritol: synthesis and their potent agonistic activity Tetrahedron 58 2002 8833 8842
33. Y. Ogawa, M. Yamamoto, H. Okada, T. Yashiki, and T. Shimamoto A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid Chem. Pharm. Bull. (Tokyo) 36 1988 1095 1103
34. M.S. Hora, R.K. Rana, J.H. Nunberg, T.R. Tice, R.M. Gilley, and M.E. Hudson Release of human serum albumin from poly(lactide-co-glycolide) microspheres Pharm. Res. 7 1990 1190 1194
35. D.T. O'Hagan, H. Jeffery, and S.S. Davis Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles Vaccine 11 1993 965 969
36. S.R. Hagen, J.D. Thompson, D.S. Snyder, and K.R. Myers Analysis of a monophosphoryl lipid A immunostimulant preparation from Salmonella minnesota R595 by high-performance liquid chromatography J. Chromatogr., A 767 1997 53 61
37. P.J. Fraker, and J.C. Speck Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a- diphrenylglycoluril Biochem. Biophys. Res. Commun. 80 1978 849 857
38. O. Cochet, J.-L. Teillaud, and C. Sautes Immunological Techniques Made Easy 1998 Wiley New York
39. R.E. Morton, and T.A. Evans Modification of the bicinchoninic acid protein assay to eliminate lipid interference in determining lipoprotein protein content Anal. Biochem. 204 1992 332 334
40. M.J. Alonso, S. Cohen, T.G. Park, R.K. Gupta, G.R. Siber, and R. Langer Determinants of release rate of tetanus vaccine from polyester microspheres Pharm. Res. 10 1993 945 953
41. R.S. Raghuvanshi, O. Singh, and A.K. Panda Correlation between in vitro release and in vivo immune response from biodegradable polymer particles entrapping tetanus toxoid Drug Deliv. 9 2002 113 120
42. D.R. Milich, F. Schodel, J.L. Hughes, J.E. Jones, and D.L. Peterson The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype J. Virol. 71 1997 2192 2201
43. A. Moore, P. McGuirk, S. Adams, W.C. Jones, J. Paul McGee, D.T. O'Hagan, and K.H.G. Mills Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells Vaccine 13 1995 1741 1749
44. H.M. Vordermeier, A.G.A. Coombes, P. Jenkins, J.P. McGee, D.T. O'Hagan, S.S. Davis, and M. Singh Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable PLG microparticles Vaccine 13 1995 1576 1582
45. J.H. Eldridge, J.K. Staas, J.A. Meulbroek, T.R. Tice, and R.M. Gilley Biodegradable and biocompatible poly(d,l-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies Infect. Immun. 59 1991 2978 2986
46. M.E. Lutsiak, D.R. Robinson, C. Coester, G.S. Kwon, and J. Samuel Analysis of poly(d,l-lactic-co-glycolic acid) nanosphere uptake by human dendritic cells and macrophages in vitro Pharm. Res. 19 2002 1480 1487
47. D.F. Nixon, C. Hioe, P.D. Chen, Z. Bian, P. Kuebler, M.L. Li, H. Qiu, X.M. Li, M. Singh, and A. Richardson Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity Vaccine 14 1996 1523 1530
48. P.R. Rogers, and M. Croft Peptide dose, affinity, and time of differentiation can contribute to the Th1/Th2 cytokine balance J. Immunol. 163 1999 1205 1213
49. J. Todt, J. Sonstein, T. Polak, G.D. Seitzman, B. Hu, and J.L. Curtis Repeated intratracheal challenge with particulate antigen modulates murine lung cytokines: 2. J. Immunol. 164 2000 4037 4047
50. K.D. Newman, J. Samuel, and G. Kwon Ovalbumin peptide encapsulated in poly(d,l-lactic-co-glycolic acid) microspheres is capable of inducing a T helper type 1 immune response J. Control. Release 54 1998 49 59
51. K.D. Newman, D.L. Sosnowski, G.S. Kwon, and J. Samuel Delivery of MUC1 mucin peptide by Poly(d,l-lactic-co-glycolic acid) microspheres induces type 1 T helper immune responses J. Pharm. Sci. 87 1998 1421 1427
52. N. Venkataprasad, A.G. Coombes, M. Singh, M. Rohde, K. Wilkinson, F. Hudecz, S.S. Davis, and H.M. Vordermeier Induction of cellular immunity to a mycobacterial antigen adsorbed on lamellar particles of lactide polymers Vaccine 17 1999 1814 1819
53. Z. Cui, and R.J. Mumper Coating of cationized protein on engineered nanoparticles results in enhanced immune responses Int. J. Pharm. 238 2002 229 239
54. J.T. Evans, J.R. Ward, J. Kern, and M.E. Johnson A single vaccination with protein-microspheres elicits a strong CD8 T-cell-mediated immune response against Mycobacterium tuberculosis antigen Mtb8.4 Vaccine 22 2004 1964 1972
55. S.G. Reed, M.R. Alderson, W. Dalemans, Y. Lobet, and Y.A.W. Skeiky Prospects for a better vaccine against tuberculosis Tuberculosis 83 2003 213 219
56. J.R. Baldridge, P. McGowan, J.T. Evans, C. Cluff, S. Mossman, D. Johnson, and D. Persing Taking a toll on human disease: toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents Expert Opin. Biol. Ther. 4 2004 1129 1138
57. J.H. Eldridge, J.K. Staas, D. Chen, P.A. Marx, T.R. Tice, and R.M. Gilley New advances in vaccine delivery systems Semin. Hematol. 30 1993 16 24 (discussion 25)
58. I. Couillin, S. Pol, M. Mancini, F. Driss, C. Brechot, P. Tiollais, and M.L. Michel Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens J. Infect. Dis. 180 1999 15 26 (erratum appears in J Infect Dis 1999 Nov;180(5):1756)
59. H. Senturk, F. Tabak, M. Akdogan, L. Erdem, A. Mert, R. Ozaras, E. Sander, G. Ozbay, and S. Badur Therapeutic vaccination in chronic hepatitis B J. Gastroenterol. Hepatol. 17 2002 72 76
60. S. Pol, B. Nalpas, F. Driss, M.-L. Michel, P. Tiollais, J. Denis, and C. Brechot Efficacy and limitations of a specific immunotherapy in chronic hepatitis B J. Hepatol. 34 2001 917 921
61. M. Triyatni, A.R. Jilbert, M. Qiao, D.S. Miller, and C.J. Burrell Protective efficacy of DNA vaccines against duck hepatitis B virus infection J. Virol. 72 1998 84 94
62. A. Thermet, C. Rollier, F. Zoulim, C. Trepo, and L. Cova Progress in DNA vaccine for prophylaxis and therapy of hepatitis B Vaccine 21 2003 659 662
63. A. Kuhober, H. Pudollek, K. Reifenberg, F. Chisari, H. Schlicht, J. Reimann, and R. Schirmbeck DNA immunization induces antibody and cytotoxic T cell responses to hepatitis B core antigen in H-2b mice J. Immunol. 156 1996 3687 3695
64. B.D. Livingston, J. Alexander, C. Crimi, C. Oseroff, E. Celis, K. Daly, L.G. Guidotti, F.V. Chisari, J. Fikes, R.W. Chesnut, and A. Sette Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans J. Immunol. 162 1999 3088 3095
65. S. Agrawal, A. Agrawal, B. Doughty, A. Gerwitz, J. Blenis, T. Van Dyke, and B. Pulendran Cutting edge: different toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos J. Immunol. 171 2003 4984 4989
66. K. Lore, M.R. Betts, J.M. Brenchley, J. Kuruppu, S. Khojasteh, S. Perfetto, M. Roederer, R.A. Seder, and R.A. Koup Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses J. Immunol. 171 2003 4320 4328
67. S. Akira, K. Takeda, and T. Kaisho Toll-like receptors: critical proteins linking innate and acquired immunity Nat. Immunol. 2 2001 675 680
68. C. Pasare, and R. Medzhitov Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells Science 299 2003 1033 1036
69. M. Diwan, P. Elamanchili, M. Cao, and J. Samuel Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery Curr. Drug Deliv. 1 2004 405 412